Journal ArticleDOI
A clinicopathologic analysis of adriamycin cardiotoxicity
Reads0
Chats0
TLDR
It is suggested that the total dose of adriamycin should be limited to less than 550 mg/m2 to permit safer use of this efficacious cancer chemotherapeutic agent.Abstract:
The cardiotoxic effects of adriamycin were studied in 399 patients treated for far-advanced carcimma. Forty-five patients (11%) exhibited transient electrocardiographs changes. Eleven others developed severe congestive heart failure. Eight of these latter patients died within 3 weeks of the onset of the cardiac decompensation. The diffuse nature of this myocardiopathy was suggested by: 1. a conspicuous decrease in the QRS voltage on the electrocardiograms; 2. rapidly occurring cardiac dilatation and ventricular failure, and 3. refractoriness to inoiropic drugs and mechanical ventricular assistance. Postmortem examination of the hearts in two cases showed a striking decrease in the number of cardiac: muscle cells present, degeneration of the remaining myocardial cells, loss o contractile substance, mitochondrial swelling, and intramitochondrial dense inclusion bodies. Congestive heart failure occurred only once in the 366 patients who were treated with less than 550 mg/m2 of adriamycin (0.27%), but there were 10 cases of cardiac failure in the 33 patients who received more than 550 mg/m2 of this drug (30%). Therefore, until more direct means are established to prevent adriamycin-induced congestive heart failure, it is suggested that the total dose of adriamycin should be limited to less than 550 mg/m2 to permit safer use of this efficacious cancer chemotherapeutic agent.read more
Citations
More filters
Journal ArticleDOI
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
TL;DR: An overview of issues confirms that anthracyclines remain “evergreen” drugs with broad clinical indications but have still an improvable therapeutic index.
Journal ArticleDOI
Risk factors for doxorubicin-induced congestive heart failure.
TL;DR: There was a continuum of increasing risk as the cumulative amount of administered drug increased, and a weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule.
Journal ArticleDOI
Doxorubicin-Induced Cardiomyopathy
TL;DR: The tumors most commonly responding to doxorubicin when it is given as a single agent or in combination with other antitumor agents include breast and esophageal carcinomas; osteosarcoma, Kaposi's sarcoma and soft-tissue sarcomas; and Hodgkin's and non-Hodgkin's lymphomas.
Journal ArticleDOI
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Steven E. Lipshultz,Steven D. Colan,Richard D. Gelber,Antonio R. Perez-Atayde,Stephen E. Sallan,Stephen P. Sanders +5 more
TL;DR: Doxorubicin therapy in childhood impairs myocardial growth in a dose-related fashion and results in a progressive increase in left ventricular afterload sometimes accompanied by reduced contractility, hypothesized to result in inadequateleft ventricular mass and clinically important heart disease in later years.
References
More filters
Journal Article
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).
TL;DR: Adriamycin produced consistent regressions in ten histologically different types of neoplastic disease, but mostly in acute lymphoblastic and chronic (myeloid and lymphocytic) leukemias, as well as in all types of malignant lymphomas, neuroblastoma, Ewing sarcoma, soft-tissue sarcomas, and chorioepithelioma of the uterus.
Journal Article
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
Journal ArticleDOI
Clinical trials with adriamycin
TL;DR: Adriamycin appears to be promising in several tumors, but maintenance therapy may be precluded by cumulative toxicity, as well as in patients with a variety of tumors.
Journal ArticleDOI
Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide
Jeffrey A. Gottlieb,Laurence H. Baker,Joseph M. Quagliana,James K. Luce,John P. Whitecar,Joseph G. Sinkovics,Saul E. Rivkin,Robert Brownlee,Emil Frei +8 more
TL;DR: Combination therapy with adriamycin and DIC appears to be an effective and promising regimen in the treatment of metastatic sarcomas.
Related Papers (5)
Adriamycin: A New Anticancer Drug with Significant Clinical Activity
Ronald H. Blum,Stephen K. Carter +1 more